248 related articles for article (PubMed ID: 28771672)
21. The p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias.
Athanasakis E; Melloni E; Rigolin GM; Agnoletto C; Voltan R; Vozzi D; Piscianz E; Segat L; Dal Monego S; Cuneo A; Secchiero P; Zauli G
Oncotarget; 2014 Dec; 5(24):12635-45. PubMed ID: 25587027
[TBL] [Abstract][Full Text] [Related]
22. NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment.
Bo MD; Del Principe MI; Pozzo F; Ragusa D; Bulian P; Rossi D; Capelli G; Rossi FM; Niscola P; Buccisano F; Bomben R; Zucchetto A; Maurillo L; de Fabritiis P; Amadori S; Gaidano G; Gattei V; Del Poeta G
Ann Hematol; 2014 Oct; 93(10):1765-74. PubMed ID: 24923451
[TBL] [Abstract][Full Text] [Related]
23. Mutation analysis of components of the Mediator kinase module in MED12 mutation-negative uterine leiomyomas.
Mäkinen N; Heinonen HR; Sjöberg J; Taipale J; Vahteristo P; Aaltonen LA
Br J Cancer; 2014 Apr; 110(9):2246-9. PubMed ID: 24642626
[TBL] [Abstract][Full Text] [Related]
24. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL.
Del Giudice I; Rossi D; Chiaretti S; Marinelli M; Tavolaro S; Gabrielli S; Laurenti L; Marasca R; Rasi S; Fangazio M; Guarini A; Gaidano G; Foà R
Haematologica; 2012 Mar; 97(3):437-41. PubMed ID: 22207691
[TBL] [Abstract][Full Text] [Related]
25. Factors targeting
Bullerdiek J; Rommel B
F1000Res; 2018; 7():359. PubMed ID: 30647905
[TBL] [Abstract][Full Text] [Related]
26. Uterine leiomyoma-linked MED12 mutations disrupt mediator-associated CDK activity.
Turunen M; Spaeth JM; Keskitalo S; Park MJ; Kivioja T; Clark AD; Mäkinen N; Gao F; Palin K; Nurkkala H; Vähärautio A; Aavikko M; Kämpjärvi K; Vahteristo P; Kim CA; Aaltonen LA; Varjosalo M; Taipale J; Boyer TG
Cell Rep; 2014 May; 7(3):654-60. PubMed ID: 24746821
[TBL] [Abstract][Full Text] [Related]
27. MED12 protein expression in breast fibroepithelial lesions: correlation with mutation status and oestrogen receptor expression.
Tan WJ; Chan JY; Thike AA; Lim JC; Md Nasir ND; Tan JS; Koh VC; Lim WK; Tan J; Ng CC; Rajasegaran V; Nagarajan S; Bay BH; Teh BT; Tan PH
J Clin Pathol; 2016 Oct; 69(10):858-65. PubMed ID: 27056456
[TBL] [Abstract][Full Text] [Related]
28. The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells.
López-Guerra M; Xargay-Torrent S; Rosich L; Montraveta A; Roldán J; Matas-Céspedes A; Villamor N; Aymerich M; López-Otín C; Pérez-Galán P; Roué G; Campo E; Colomer D
Leukemia; 2015 Jan; 29(1):96-106. PubMed ID: 24781018
[TBL] [Abstract][Full Text] [Related]
29. LPL gene expression is associated with poor prognosis in CLL and closely related to NOTCH1 mutations.
Kristensen L; Kristensen T; Abildgaard N; Royo C; Frederiksen M; Mourits-Andersen T; Campo E; Møller MB
Eur J Haematol; 2016 Aug; 97(2):175-82. PubMed ID: 26558352
[TBL] [Abstract][Full Text] [Related]
30. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.
Puente XS; Pinyol M; Quesada V; Conde L; Ordóñez GR; Villamor N; Escaramis G; Jares P; Beà S; González-Díaz M; Bassaganyas L; Baumann T; Juan M; López-Guerra M; Colomer D; Tubío JM; López C; Navarro A; Tornador C; Aymerich M; Rozman M; Hernández JM; Puente DA; Freije JM; Velasco G; Gutiérrez-Fernández A; Costa D; Carrió A; Guijarro S; Enjuanes A; Hernández L; Yagüe J; Nicolás P; Romeo-Casabona CM; Himmelbauer H; Castillo E; Dohm JC; de Sanjosé S; Piris MA; de Alava E; San Miguel J; Royo R; Gelpí JL; Torrents D; Orozco M; Pisano DG; Valencia A; Guigó R; Bayés M; Heath S; Gut M; Klatt P; Marshall J; Raine K; Stebbings LA; Futreal PA; Stratton MR; Campbell PJ; Gut I; López-Guillermo A; Estivill X; Montserrat E; López-Otín C; Campo E
Nature; 2011 Jun; 475(7354):101-5. PubMed ID: 21642962
[TBL] [Abstract][Full Text] [Related]
31. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome.
Villamor N; Conde L; Martínez-Trillos A; Cazorla M; Navarro A; Beà S; López C; Colomer D; Pinyol M; Aymerich M; Rozman M; Abrisqueta P; Baumann T; Delgado J; Giné E; González-Díaz M; Hernández JM; Colado E; Payer AR; Rayon C; Navarro B; José Terol M; Bosch F; Quesada V; Puente XS; López-Otín C; Jares P; Pereira A; Campo E; López-Guillermo A
Leukemia; 2013 Apr; 27(5):1100-6. PubMed ID: 23295735
[TBL] [Abstract][Full Text] [Related]
32. Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia.
Jethwa A; Hüllein J; Stolz T; Blume C; Sellner L; Jauch A; Sill M; Kater AP; te Raa GD; Geisler C; van Oers M; Dietrich S; Dreger P; Ho AD; Paruzynski A; Schmidt M; von Kalle C; Glimm H; Zenz T
Br J Haematol; 2013 Nov; 163(4):496-500. PubMed ID: 24032483
[TBL] [Abstract][Full Text] [Related]
33. MED12 somatic mutations encompassing exon 2 associated with benign breast fibroadenomas and not breast carcinoma in Indian women.
Darooei M; Khan F; Rehan M; Zubeda S; Jeyashanker E; Annapurna S; Shah A; Maddali S; Hasan Q
J Cell Biochem; 2019 Jan; 120(1):182-191. PubMed ID: 30230586
[TBL] [Abstract][Full Text] [Related]
34. Notch signaling promotes disease initiation and progression in murine chronic lymphocytic leukemia.
Tardivon D; Antoszewski M; Zangger N; Nkosi M; Sordet-Dessimoz J; Hendriks R; Koch U; Radtke F
Blood; 2021 Jun; 137(22):3079-3092. PubMed ID: 33512383
[TBL] [Abstract][Full Text] [Related]
35. IL-4-dependent Jagged1 expression/processing is associated with survival of chronic lymphocytic leukemia cells but not with Notch activation.
De Falco F; Del Papa B; Baldoni S; Sabatini R; Falzetti F; Di Ianni M; Martelli MP; Mezzasoma F; Pelullo M; Marconi P; Sportoletti P; Screpanti I; Rosati E
Cell Death Dis; 2018 Nov; 9(12):1160. PubMed ID: 30478302
[TBL] [Abstract][Full Text] [Related]
36. Next-generation sequencing in chronic lymphocytic leukemia.
Villamor N; López-Guillermo A; López-Otín C; Campo E
Semin Hematol; 2013 Oct; 50(4):286-95. PubMed ID: 24246696
[TBL] [Abstract][Full Text] [Related]
37. Outcomes in CLL patients with NOTCH1 regulatory pathway mutations.
Helbig DR; Abu-Zeinah G; Bhavsar E; Christos PJ; Furman RR; Allan JN
Am J Hematol; 2021 Jun; 96(6):E187-E189. PubMed ID: 33625731
[No Abstract] [Full Text] [Related]
38. Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: A comparison of cellular, cytogenetic, molecular, and clinical features.
Morabito F; Mosca L; Cutrona G; Agnelli L; Tuana G; Ferracin M; Zagatti B; Lionetti M; Fabris S; Maura F; Matis S; Gentile M; Vigna E; Colombo M; Massucco C; Recchia AG; Bossio S; De Stefano L; Ilariucci F; Musolino C; Molica S; Di Raimondo F; Cortelezzi A; Tassone P; Negrini M; Monti S; Rossi D; Gaidano G; Ferrarini M; Neri A
Clin Cancer Res; 2013 Nov; 19(21):5890-900. PubMed ID: 24036852
[TBL] [Abstract][Full Text] [Related]
39. Notch signaling sustains the expression of Mcl-1 and the activity of eIF4E to promote cell survival in CLL.
De Falco F; Sabatini R; Del Papa B; Falzetti F; Di Ianni M; Sportoletti P; Baldoni S; Screpanti I; Marconi P; Rosati E
Oncotarget; 2015 Jun; 6(18):16559-72. PubMed ID: 26041884
[TBL] [Abstract][Full Text] [Related]
40. MED12 mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways.
Laé M; Gardrat S; Rondeau S; Richardot C; Caly M; Chemlali W; Vacher S; Couturier J; Mariani O; Terrier P; Bièche I
Oncotarget; 2016 Dec; 7(51):84428-84438. PubMed ID: 27806318
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
